<?xml version="1.0" encoding="UTF-8" standalone="no" ?>
<rss version="2.0">
  <channel>
    <title>Staal, F.J.T.</title>
    <link>http://repub.eur.nl/res/aut/1904/</link>
    <description>List of Publications</description>
    <language>en</language>
    <image>
      <url>http://repub.eur.nl/static-eur/img/logo.png</url>
      <title>RePub, Erasmus University Rotterdam</title>
      <link>http://repub.eur.nl</link>
    </image>
    <item>
      <title>Combined TCRG and TCRA TREC analysis reveals increased peripheral T-lymphocyte but constant intra-thymic proliferative history upon ageing (Article)</title>
      <link>http://repub.eur.nl/res/pub/37317/</link>
      <pubDate>2013-03-01T00:00:00Z</pubDate>
      <description>T-cell receptor (TCR) repertoire diversity, thymic output, clonal size and peripheral T-lymphocyte numbers largely depend on intra-thymic and post-thymic T-lymphocyte proliferation. However, quantitative insight into thymocyte and T-lymphocyte proliferation is still lacking. We developed a new TCRG-based TCR excision circle (TREC) assay, the Vγ-Jγ TREC assay, which we used together with an adjusted δREC-ψJα TREC assay to quantify the proliferative history of human thymocyte and T-lymphocyte subpopulations from children and adults. This revealed that thymocytes undergo ∼6-8 intra-thymic cell divisions from the double negative (DN) 3 developmental stage onwards, which appeared independent of age. Thus thymocyte proliferation after the DN3 developmental stages is stable and therefore not contributing to the reduced thymic output upon ageing. Cord blood naive T lymphocytes had already undergone ∼2-3 post-thymic cell divisions, which increased to ∼6-7 cell divisions in naive T lymphocytes of middle-aged adults, indicating the importance of homeostatic naive T-lymphocyte proliferation from a young age onwards in the maintenance of peripheral T-lymphocyte numbers. In conclusion, our data provide quantitative insight into the proliferative history of thymocyte and T-lymphocyte subpopulations and alterations herein upon ageing. This novel TREC assay approach could prove valuable in immune status monitoring in a variety of conditions. </description>
    </item> <item>
      <title>Morbidly obese human subjects have increased peripheral blood CD4 + T cells with skewing toward a Treg- and Th2-dominated phenotype (Article)</title>
      <link>http://repub.eur.nl/res/pub/38280/</link>
      <pubDate>2012-02-01T00:00:00Z</pubDate>
      <description>Obesity is associated with local T-cell abnormalities in adipose tissue. Systemic obesity-related abnormalities in the peripheral blood T-cell compartment are not well defined. In this study, we investigated the peripheral blood T-cell compartment of morbidly obese and lean subjects. We determined all major T-cell sub-populations via six-color flow cytometry, including CD8+and CD4+T cells, CD4+T-helper (Th) subpopulations, and natural CD4+CD25+FoxP3+T-regulatory (Treg) cells. Moreover, molecular analyses to assess thymic output, T-cell proliferation (T-cell receptor excision circle analysis), and T-cell receptor-β (TCRB) repertoire (GeneScan analysis) were performed. In addition, we determined plasma levels of proinflammatory cytokines and cytokines associated with Th subpopulations and T-cell proliferation. Morbidly obese subjects had a selective increase in peripheral blood CD4+naive, memory, natural CD4+CD25+FoxP3+Treg, and Th2 T cells, whereas CD8+T cells were normal. CD4+and CD8+T-cell proliferation was increased, whereas the TCRB repertoire was not significantly altered. Plasma levels of cytokines CCL5 and IL-7 were elevated. CD4+T-cell numbers correlated positively with fasting insulin levels. The peripheral blood T-cell compartment of morbidly obese subjects is characterized by increased homeostatic T-cell proliferation to which cytokines IL-7 and CCL5, among others, might contribute. This is associated with increased CD4+T cells, with skewing toward a Treg- and Th2-dominated phenotype, suggesting a more anti-inflammatory set point. </description>
    </item> <item>
      <title>Signal transduction pathways regulating hematopoietic stem cell biology: Introduction to a series of Spotlight Reviews (Article)</title>
      <link>http://repub.eur.nl/res/pub/37211/</link>
      <pubDate>2012-01-01T00:00:00Z</pubDate>
      <description></description>
    </item> <item>
      <title>Correction of murine Rag1 deficiency by self-inactivating lentiviral vector-mediated gene transfer (Article)</title>
      <link>http://repub.eur.nl/res/pub/26260/</link>
      <pubDate>2011-09-01T00:00:00Z</pubDate>
      <description>Severe combined immunodeficiency (SCID) patients with an inactivating mutation in recombination activation gene 1 (RAG1) lack B and T cells due to the inability to rearrange immunoglobulin (Ig) and T-cell receptor (TCR) genes. Gene therapy is a valid treatment option for RAG-SCID patients, especially for patients lacking a suitable bone marrow donor, but developing such therapy has proven challenging. As a preclinical model for RAG-SCID, we used Rag1-/-mice and lentiviral self-inactivating (SIN) vectors harboring different internal elements to deliver native or codon-optimized human RAG1 sequences. Treatment resulted in the appearance of B and T cells in peripheral blood and developing B and T cells were detected in central lymphoid organs. Serum Ig levels and Ig and TCR VΒ gene segment usage was comparable to wild-type (WT) controls, indicating that RAG-mediated rearrangement took place. Remarkably, relatively low frequencies of B cells produced WT levels of serum immunoglobulins. Upon stimulation of the TCR, corrected spleen cells proliferated and produced cytokines. In vivo challenge resulted in production of antigen-specific antibodies. No leukemia development as consequence of insertional mutagenesis was observed. The functional reconstitution of the B-as well as the T-cell compartment provides proof-of-principle for therapeutic RAG1 gene transfer in Rag1-/-mice using lentiviral SIN vectors. </description>
    </item> <item>
      <title>Effective treatment of psoriasis with narrow-band UVB phototherapy is linked to suppression of the IFN and Th17 pathways (Article)</title>
      <link>http://repub.eur.nl/res/pub/33387/</link>
      <pubDate>2011-07-01T00:00:00Z</pubDate>
      <description>Narrow-band ultraviolet-B (NB-UVB) phototherapy is an effective treatment for psoriasis. The molecular mechanisms underlying its efficacy are incompletely understood. To identify NB-UVB-induced molecular pathways that may account for its anti-inflammatory efficacy, gene expression profiling was performed using epidermal RNA from lesional and nonlesional skin from patients with psoriasis undergoing NB-UVB therapy. Downregulation of Th17 signaling pathway was observed during NB-UVB therapy in psoriatic epidermis. Strong inhibition of the Th17 pathway by UVB was confirmed in an ex vivo organ culture system by demonstrating reduced signal transducer and activator of transcription 3 (STAT3) phosphorylation and Β-defensin-2 production. These results were further substantiated by demonstrating that NB-UVB inhibited the Th17-dependent psoriasis-like dermatitis in mice. Other pathways affected by NB-UVB therapy include the IFN signaling pathway, epidermal differentiation, and other well-known therapeutic targets in psoriasis, such as the glucocorticoid, vitamin D, peroxisome proliferator-activated receptor, and IL-4 signaling pathways. In conclusion, clinical improvement of psoriasis by NB-UVB is linked to suppression of Th17 and type I and type II IFN signaling pathways, which are critical in the pathogenesis of the disease. Our results show that clinically effective NB-UVB therapy is based on suppression of a broad range of important molecular pathways in psoriatic skin. </description>
    </item> <item>
      <title>Integrated Transcript and Genome Analyses Reveal NKX2-1 and MEF2C as Potential Oncogenes in T Cell Acute Lymphoblastic Leukemia (Article)</title>
      <link>http://repub.eur.nl/res/pub/34512/</link>
      <pubDate>2011-04-12T00:00:00Z</pubDate>
      <description>To identify oncogenic pathways in T cell acute lymphoblastic leukemia (T-ALL), we combined expression profiling of 117 pediatric patient samples and detailed molecular-cytogenetic analyses including the Chromosome Conformation Capture on Chip (4C) method. Two T-ALL subtypes were identified that lacked rearrangements of known oncogenes. One subtype associated with cortical arrest, expression of cell cycle genes, and ectopic NKX2-1 or NKX2-2 expression for which rearrangements were identified. The second subtype associated with immature T cell development and high expression of the MEF2C transcription factor as consequence of rearrangements of MEF2C, transcription factors that target MEF2C, or MEF2C-associated cofactors. We propose NKX2-1, NKX2-2, and MEF2C as T-ALL oncogenes that are activated by various rearrangements. </description>
    </item> <item>
      <title>Correction of B-cell development in Btk-deficient mice using lentiviral vectors with codon-optimized human BTK (Article)</title>
      <link>http://repub.eur.nl/res/pub/20311/</link>
      <pubDate>2010-09-01T00:00:00Z</pubDate>
      <description>X-linked agammaglobulinemia (XLA) is the most common primary immunodeficiency (PID) in man and caused by mutations in the Bruton's tyrosine kinase (BTK) gene. XLA is characterized by a B-cell differentiation arrest in bone marrow, absence of mature B cells and immunoglobulins (Igs), and recurrent bacterial infections. We used self-inactivating lentiviral vectors expressing codon-optimized human BTK under the control of three different ubiquitous or B cell-specific promoters. Btk-/- mice engrafted with transduced cells showed correction of both precursor B-cell and peripheral B-cell development. Lentiviral vectors containing the wildtype BTK sequence did not correct the phenotype. All treated mice with codon-optimized BTK exhibited the recovery of B1 cells in the peritoneal cavity, and of serum IgM and IgG3 levels. Calcium mobilization responses upon B-cell receptor stimulation as well as in vivo responses to T cell-independent antigens were restored. Viral promoters overexpressing BTK &gt;100-fold above normal resulted in erythro-myeloid proliferations independent of insertional mutagenesis. However, transplantation into secondary Btk-/- recipients using cellular promoters resulted in functional restoration of peripheral B cells and IgM levels, without any adverse effects. In conclusion, transduction of human BTK corrects B-cell development and antigen-specific antibody responses in Btk-/- mice, thus indicating the feasibility of lentiviral gene therapy for XLA, provided that BTK expression does not vastly exceed normal levels.Leukemia advance online publication, 24 June 2010; doi:10.1038/leu.2010.140.</description>
    </item> <item>
      <title>Detection of fusion genes at the protein level in leukemia patients via the flow cytometric immunobead assay (Article)</title>
      <link>http://repub.eur.nl/res/pub/22073/</link>
      <pubDate>2010-09-01T00:00:00Z</pubDate>
      <description>Nowadays, the presence of specific genetic aberrations is progressively used for classification and treatment stratification, because acute leukemias with the same oncogenetic aberration generally form a clinically and diagnostically homogenous disease entity with comparable prognosis. Many oncogenetic aberrations in acute leukemias result in a fusion gene, which is transcribed into fusion transcripts and translated into fusion proteins, which are assumed to play a critical role in the oncogenetic process. Fusion gene aberrations are detected by karyotyping, FISH, or RT-PCR analysis. However, these molecular genetic techniques are laborious and time consuming, which is in contrast to flow cytometric techniques. Therefore we developed a flow cytometric immunobead assay for detection of fusion proteins in lysates of leukemia cell samples by use of a bead-bound catching antibody against one side of the fusion protein and fluorochrome-conjugated detection antibody. So far, we have been able to design such fusion protein immunobead assays for BCR-ABL, PML-RARA, TEL-AML1, E2A-PBX1, MLL-AF4, AML1-ETO and CBFB-MYH11. The immunobead assay for detection of fusion proteins can be performed within 3 to 4 hours in a routine diagnostic setting, without the need of special equipment other than a flow cytometer. The novel immunobead assay will enable fast and easy classification of acute leukemia patients that express fusion proteins. Such patients can be included at an early stage in the right treatment protocols, much faster than by use of current molecular techniques. The immunobead assay can be run in parallel to routine immunophenotyping and is particularly attractive for clinical settings without direct access to molecular diagnostics.</description>
    </item> <item>
      <title>Wnt3a nonredundantly controls hematopoietic stem cell function and its deficiency results in complete absence of canonical Wnt signaling (Article)</title>
      <link>http://repub.eur.nl/res/pub/21105/</link>
      <pubDate>2010-07-01T00:00:00Z</pubDate>
      <description></description>
    </item> <item>
      <title>Wnt signaling in hematopoiesis: Crucial factors for self-renewal, proliferation, and cell fate decisions (Article)</title>
      <link>http://repub.eur.nl/res/pub/28027/</link>
      <pubDate>2010-04-01T00:00:00Z</pubDate>
      <description>A large number of studies from many different laboratories have implicated the Wnt signaling pathway in regulation of hematopoiesis. However, different inducible gain- and loss-of-function approaches yielded controversial and some times contradictory results. In this prospect we will review the current ideas on Wnt signaling in hematopoiesis and early lymphopoiesis. Reviewing this large body of knowledge let us to hypothesize that different levels of activation of the pathway, dosages of Wnt signaling required and the interference by other signals in the context of Wnt activation collectively explain these controversies. Besides differences in dosage, differences in biological function of Wnt proteins in various blood cell types also is a major factor to take into account. Our own work has shown that while in the thymus Wnt signaling provides cytokine-like, proliferative stimuli to developing thymocytes, canonical Wnt signaling in HSC regulates cell fate decisions, in particular self-renewal versus differentiation. </description>
    </item> <item>
      <title>Genome-wide expression analysis of paired diagnosis-relapse samples in ALL indicates involvement of pathways related to DNA replication, cell cycle and DNA repair, independent of immune phenotype (Article)</title>
      <link>http://repub.eur.nl/res/pub/28079/</link>
      <pubDate>2010-03-01T00:00:00Z</pubDate>
      <description>Almost a quarter of pediatric patients with acute lymphoblastic leukemia (ALL) suffer from relapses. The biological mechanisms underlying therapy response and development of relapses have remained unclear. In an attempt to better understand this phenomenon, we have analyzed 41 matched diagnosis-relapse pairs of ALL patients using genome-wide expression arrays (82 arrays) on purified leukemic cells. In roughly half of the patients, very few differences between diagnosis and relapse samples were found (stable group), suggesting that mostly extra-leukemic factors (for example, drug distribution, drug metabolism, compliance) contributed to the relapse. Therefore, we focused our further analysis on 20 sample pairs with clear differences in gene expression (skewed group), reasoning that these would allow us to better study the biological mechanisms underlying relapsed ALL. After finding the differences between diagnosis and relapse pairs in this group, we identified four major gene clusters corresponding to several pathways associated with changes in cell cycle, DNA replication, recombination and repair, as well as B-cell developmental genes. We also identified cancer genes commonly associated with colon carcinomas and ubiquitination to be upregulated in relapsed ALL. Thus, about half of the relapses are due to the selection or emergence of a clone with deregulated expression of genes involved in pathways that regulate B-cell signaling, development, cell cycle, cellular division and replication. </description>
    </item> <item>
      <title>Response (Article)</title>
      <link>http://repub.eur.nl/res/pub/26918/</link>
      <pubDate>2009-12-01T00:00:00Z</pubDate>
      <description></description>
    </item> <item>
      <title>WNT proteins: Environmental factors regulating HSC fate in the niche (Article)</title>
      <link>http://repub.eur.nl/res/pub/17786/</link>
      <pubDate>2009-10-15T00:00:00Z</pubDate>
      <description>The Wnt signaling pathway has been implicated in regulation of hematopoiesis through a plethora of studies from many different laboratories. However, different inducible gain- and loss-of-function approaches retrieved controversial and sometimes contradictory results. Different levels of activation of the pathway, dosages of Wnt signaling required, and the interference by other signals in the context of Wnt activation collectively explain these controversies. Gain-of-function or in vitro exposure to WNT proteins and more specifically WNT3a was shown to enhance hematopoietic stem cell (HSC) activity, but its exact role was still not completely understood. In a recent study we analyzed the hematopoietic system of mice deficient for this specific Wnt gene. Wnt3a deficiency results in early embryonic lethality around embryonic day 12.5 (E12.5), precluding analysis in adult mice, but allowing hematopoiesis to be studied in fetal liver (FL) and in the just colonized thymic rudiment. Notably, we showed that long-term HSCs and multipotent progenitors are reduced in FL and have severely reduced long-term reconstitution capacity as observed in serial transplantation assays. Of interest, deficiency in Wnt3a leads to complete abolition of canonical Wnt signaling in FL hematopoietic stem and progenitor cells. This HSC deficiency is not explained by altered cell cycle or survival and is irreversible, since it cannot be restored by transplantation into Wnt3a-competent mice. In addition, Wnt3a deficiency differentially affects myeloid and B-lymphoid lineages, with myeloid cells being affected at the progenitor level, while B lymphopoiesis is apparently unaffected. Immature thymocytes, however, were reduced in cell numbers due to lack of Wnt3a production by the thymic microenvironment. Our results show that while in the thymus Wnt3a provides cytokine-like, proliferative stimuli to developing thymocyte Wnt3a regulates cell fate decisions of FL HSC in a nonredundant way.</description>
    </item> <item>
      <title>Differentiation of bone marrow-derived endothelial progenitor cells is shifted into a proinflammatory phenotype by hyperglycemia (Article)</title>
      <link>http://repub.eur.nl/res/pub/32590/</link>
      <pubDate>2009-05-01T00:00:00Z</pubDate>
      <description>Bone marrow (BM)-derived endothelial progenitor cells (EPC) contribute to vascular maintenance by participating in angio- genesis, re-endothelialization, and remodeling. Myeloid progenitor cells in the BM are functionally and quantitatively an important precursor pool for cells that contribute to these processes. However, these precursor pools in the BM also give rise to important effector cells of the innate immune system, such as macrophages and dendritic cells. We hypothesized that the disturbed repair responses that are being observed in diabetes mellitus are also related to an effect on functional and differentiation characteristics at the level of this bone marrow precursor pool. Indeed, we observed that bone marrow differentiation cultures for EPC, macrophages (Mph), or dendritic cells (DC) from hyperglycemic BM yielded 40% fewer EPC and 50% more Mph compared with control BM. These changes were directly related to the hemoglobin A1Clevels of the donor mice. BM-derived DC numbers were not affected by hyperglycemia.The composition of the BM was not altered; in particular, the numbers of CD31+/Ly6C+cells, which serve as common progenitors for EPC,Mph,and DC,were unaffected. In addition,BM-derived EPC from hyperglycemic mice were less angiogenic and more proinflammatory in regards to endocytosis, T-cell activation, and interleukin 12 production. HMG-CoA (3-hydroxy-3-methylglutaryl coenzyme A) reductase inhibition by statin supplementation of the culture medium counteracted these hyperglycemia-induced changes. Our study results show that hyperglycemia alters the differentiation fate of BM precursor cells, reducing the potential to generate vascular regenerative cells and favoring the development of proinflammatory cells. </description>
    </item> <item>
      <title>Flow cytometric immunobead assay for the detection of BCR-ABL fusion proteins in leukemia patients (Article)</title>
      <link>http://repub.eur.nl/res/pub/24568/</link>
      <pubDate>2009-04-24T00:00:00Z</pubDate>
      <description>BCR-ABL fusion proteins show increased signaling through their ABL tyrosine kinase domain, which can be blocked by specific inhibitors, thereby providing effective treatment. This makes detection of BCR-ABL aberrations of utmost importance for diagnosis, classification and treatment of leukemia patients. BCR-ABL aberrations are currently detected by karyotyping, fluorescence in situ hybridization (FISH) or PCR techniques, which are time consuming and require specialized facilities. We developed a simple flow cytometric immunobead assay for detection of BCR-ABL fusion proteins in cell lysates, using a bead-bound anti-BCR catching antibody and a fluorochrome-conjugated anti-ABL detection antibody. We noticed protein stability problems in lysates caused by proteases from mature myeloid cells. This problem could largely be solved by adding protease inhibitors in several steps of the immunobead assay. Testing of 145 patient samples showed fully concordant results between the BCR-ABL immunobead assay and reverse transcriptase PCR of fusion gene transcripts. Dilution experiments with BCR-ABL positive cell lines revealed sensitivities of at least 1%. We conclude that the BCR-ABL immunobead assay detects all types of BCR-ABL proteins in leukemic cells with high specificity and sensitivity. The assay does not need specialized laboratory facilities other than a flow cytometer, provides results within ∼4h, and can be run in parallel to routine immunophenotyping.</description>
    </item> <item>
      <title>Wnt3a deficiency irreversibly impairs hematopoietic stem cell self-renewal and leads to defects in progenitor cell differentiation (Article)</title>
      <link>http://repub.eur.nl/res/pub/19345/</link>
      <pubDate>2009-01-15T00:00:00Z</pubDate>
      <description>Canonical Wnt signaling has been implicated in various aspects of hematopoiesis. Its role is controversial due to different outcomes between various inducible Wnt-signaling loss-of-function models and also compared with gain-of-function systems. We therefore studied a mouse deficient for a Wnt gene that seemed to play a nonredundant role in hematopoiesis. Mice lacking Wnt3a die prenatally around embryonic day (E) 12.5, allowing fetal hematopoiesis to be studied using in vitro assays and transplantation into irradiated recipient mice. Here we show that Wnt3a deficiency leads to a reduction in the numbers of hematopoietic stem cells (HSCs) and progenitor cells in the fetal liver (FL) and to severely reduced reconstitution capacity as measured in secondary transplantation assays. This deficiency is irreversible and cannot be restored by transplantation into Wnt3a competent mice. The impaired long-term repopulation capacity of Wnt3a-/- HSCs could not be explained by altered cell cycle or survival of primitive progenitors. Moreover, Wnt3a deficiency affected myeloid but not B-lymphoid development at the progenitor level, and affected immature thymocyte differentiation. Our results show that Wnt3a signaling not only provides proliferative stimuli, such as for immature thymocytes, but also regulates cell fate decisions of HSC during hematopoiesis.</description>
    </item> <item>
      <title>Isolation of human and mouse hematopoietic stem cells. (Article)</title>
      <link>http://repub.eur.nl/res/pub/15560/</link>
      <pubDate>2009-01-01T00:00:00Z</pubDate>
      <description>Hematopoietic stem cells (HSC) are rare with estimated frequencies of 1 in 10,000 bone marrow cells and 1 in every 100,000 blood cells. The most important characteristic of HSC is their capacity to provide complete restoration of all blood cell lineages after bone marrow ablation. Therefore they are considered as the ideal targets for various clinical applications including stem cell transplantation and gene therapy. In adult mice and men, the main stem cell source is the bone marrow. For clinical applications HSC derived from umbilical cord blood (UCB) and G-CSF mobilized peripheral blood (PB) have been demonstrated to have several advantages compared to bone marrow; therefore, they are slowly replacing BM as alternative source of stem cells. The mouse is the model organism of choice for immunological and hematological research; therefore, studies of murine HSC are an important research topic. Here we described the most often used protocols and methods to isolate human and mouse HSC to high purity.</description>
    </item> <item>
      <title>Sola dosis facit venenum. Leukemia in gene therapy trials: A question of vectors, inserts and dosage? (Article)</title>
      <link>http://repub.eur.nl/res/pub/14548/</link>
      <pubDate>2008-10-23T00:00:00Z</pubDate>
      <description>In clinical gene therapy trials for X-linked severe combined immunodeficiency, the development of leukemia has come up as a severe adverse effect. In all five cases, T-cell acute lymphoblastic leukemia (T-ALL) occurred as a direct consequence of insertional mutagenesis by the retrovirus used to deliver the therapeutic gene. Here, we review the mechanisms of insertional mutagenesis, the fuction of the Il2RG gene and the future developments in the field. New lentiviral and γ retroviral vectors can significantly improve the safety profile of the tools used but still carry the risk of insertional mutagenesis, as shown in this issue of Leukemia. Finally, the unfortunate side effects of gene therapy have given more insight into the development of human T-ALL.</description>
    </item> <item>
      <title>Distinct monocyte Gene-Expression profiles in autoimmune diabetes (Article)</title>
      <link>http://repub.eur.nl/res/pub/29155/</link>
      <pubDate>2008-10-01T00:00:00Z</pubDate>
      <description>OBJECTIVE-There is evidence that monocytes of patients with type 1 diabetes show proinflammatory activation and disturbed migration/adhesion, but the evidence is inconsistent. Our hypothesis is that monocytes are distinctly activated/disturbed in different subforms of autoimmune diabetes. RESEARCH DESIGN AND METHODS-We studied patterns of inflammatory gene expression in monocytes of patients with type 1 diabetes (juvenile onset, n = 30; adult onset, n = 30) and latent autoimmune diabetes of the adult (LADA) (n = 30) (controls subjects, n = 49; type 2 diabetic patients, n = 30) using quantitative PCR. We tested 25 selected genes: 12 genes detected in a prestudy via whole-genome analyses plus an additional 13 genes identified as part of a monocyte inflammatory signature previously reported. RESULTS-We identified two distinct monocyte gene expression clusters in autoimmune diabetes. One cluster (comprising 12 proinflammatory cytokine/compound genes with a putative key gene PDE4B) was detected in 60% of LADA and 28% of adult-onset type 1 diabetic patients but in only 10% of juvenile - onset type 1 diabetic patients. A second cluster (comprising 10 chemotaxis, adhesion, motility, and metabolism genes) was detected in 43% of juvenile-onset type 1 diabetic and 33% of LADA patients but in only 9% of adult-onset type 1 diabetic patients. CONCLUSIONS-Subgroups of type 1 diabetic patients show an abnormal monocyte gene expression with two profiles, supporting a concept of heterogeneity in the pathogenesis of autoimmune diabetes only partly overlapping with the presently known diagnostic categories. </description>
    </item> <item>
      <title>Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients (Article)</title>
      <link>http://repub.eur.nl/res/pub/32328/</link>
      <pubDate>2008-09-02T00:00:00Z</pubDate>
      <description>X-linked SCID (SCID-X1) is amenable to correction by gene therapy using conventional gammaretroviral vectors. Here, we describe the occurrence of clonal T cell acute lymphoblastic leukemia (T-ALL) promoted by insertional mutagenesis in a completed gene therapy trial of 10 SCID-X1 patients. Integration of the vector in an antisense orientation 35 kb upstream of the protooncogene LIM domain only 2 (LMO2) caused overexpression of LMO2 in the leukemic clone. However, leukemogenesis was likely precipitated by the acquisition of other genetic abnormalities unrelated to vector insertion, including a gain-of-function mutation in NOTCH1, deletion of the tumor suppressor gene locus cyclin-dependent kinase 2A (CDKN2A), and translocation of the TCR-β region to the STIL-TAL1 locus. These findings highlight a general toxicity of endogenous gammaretroviral enhancer elements and also identify a combinatorial process during leukemic evolution that will be important for risk stratification and for future protocol design.</description>
    </item> <item>
      <title>WNT signalling in the immune system: WNT is spreading its wings (Article)</title>
      <link>http://repub.eur.nl/res/pub/30330/</link>
      <pubDate>2008-08-01T00:00:00Z</pubDate>
      <description>WNT proteins are secreted morphogens that are required for basic developmental processes, such as cell-fate specification, progenitor-cell proliferation and the control of asymmetric cell division, in many different species and organs. In blood and immune cells, WNT signalling controls the proliferation of progenitor cells and might also affect the cell-fate decisions of stem cells. Recent studies indicate that WNT proteins also regulate effector T-cell development, regulatory T-cell activation and dendritic-cell maturation. WNT signalling seems to function as a universal mechanism in leukocytes to establish a pool of undifferentiated cells for further selection, effector-cell maturation and terminal differentiation. WNT signalling is therefore subject to strict molecular control, and dysregulated WNT signalling is implicated in the development of haematological malignancies. </description>
    </item> <item>
      <title>The canonical Wnt signaling pathway plays an important role in lymphopoiesis and hematopoiesis (Article)</title>
      <link>http://repub.eur.nl/res/pub/15923/</link>
      <pubDate>2008-07-01T00:00:00Z</pubDate>
      <description>The evolutionarily conserved canonical Wnt-β-catenin-T cell factor (TCF)/lymphocyte enhancer binding factor (LEF) signaling pathway regulates key checkpoints in the development of various tissues. Therefore, it is not surprising that a large body of gain-of-function and loss-of-function studies implicate Wnt-β-catenin signaling in lymphopoiesis and hematopoiesis. In contrast, recent papers have reported that Mx-Cre-mediated conditional deletion of β-catenin and/ or its homolog γ-catenin (plakoglobin) did not impair hematopoiesis or lymphopoiesis. However, these studies also report that TCF reporter activity remains active in β-catenin- and γ-catenin-deficient hematopoietic stem cells and all cells derived from these precursors, indicating that the canonical Wnt signaling pathway was not abrogated. Therefore, these studies in fact show that the canonical Wnt signaling pathway is important in hematopoiesis and lymphopoiesis, even though the molecular basis for the induction of the reporter activity is currently unknown. In this perspective, we provide a broad background to the field with a discussion of the available data and create a framework within which the available and future studies may be evaluated.</description>
    </item> <item>
      <title>The role of cortistatin in the human immune system (Article)</title>
      <link>http://repub.eur.nl/res/pub/29711/</link>
      <pubDate>2008-05-14T00:00:00Z</pubDate>
      <description>Cortistatin (CST) is a recently described neuropeptide that shares high homology with somatostatin (somatotropin release-inhibiting factor, SRIF) and binds with high affinity to all somatostatin (sst) receptor subtypes. CST is currently known to have a widespread distribution in many human organs including the immune system. The activities specific to CST may be partially attributable to its binding to the growth hormone secretagogue (GHS)-receptor (GHS-R) and the orphan G-protein-coupled receptor MrgX2. Human immune cells produce CST, whereas macrophage lineage and activated endothelium express sst2, and human lymphocytes express sst3. The human thymus expresses sst1, 2, 3, MrgX2 and almost all immune cells express GHS-R. Moreover, at this very moment promising research with CST in experimental animal models is being performed. On the basis of these promising results, studies aiming to further evaluate the possibilities of CST as a therapeutic agent in human immune-mediated inflammatory diseases are warranted. </description>
    </item> <item>
      <title>Dialysis-related systemic microinflammation is associated with specific genomic patterns (Article)</title>
      <link>http://repub.eur.nl/res/pub/29953/</link>
      <pubDate>2008-05-01T00:00:00Z</pubDate>
      <description>Background. Although several reports have focused on the clinical importance of the systemic microinflammatory state in the uraemic population, the relationship between the activation of a specific transcriptome and the development of this condition is still not completely defined. Methods. Thirty haemodialysis (HD), 30 peritoneal dialysis (PD) and 30 chronic kidney disease (CKD) patients were enrolled in our study. For all patients, serum C-reactive protein (CRP) and ferritin levels were determined. In addition, the expression level of 234 inflammatory responses and oxidative stress pathway genes was measured, using oligonucleotide microarray chips (HG-U133A, Affymetrix), in peripheral blood mononuclear cells of 24 randomly selected patients (8 HD, 8 PD and 8 CKD). Results. HD patients demonstrated higher CRP and ferritin levels compared to PD and CKD patients (P &lt; 0.001). Statistical analysis identified 10 genes able to discriminate CKD from HD and PD patients (FDR = 5%, P &lt; 0.001) and significantly correlated to CRP levels. All together, these genes were able to predict inflammation with an accuracy of 87% (P &lt; 0.001). Among the selected genes there were those encoding for key regulators of inflammation and oxidative stress (e.g. RELA, GSS). Interestingly, only three inflammatory genes (MIF, IL8RB and CXCL12) were still significantly associated with inflammation when included in a multivariate analysis. RT-PCR for RELA, MIF, CXCL12 and western blots for IL8RB and GSS, using 66 patients, validated the microarray results. Conclusions. This study may help to better understand the physiopathology of the systemic inflammatory state in CKD and dialysis patients and to identify new target genes potentially useful for future bio-molecular studies and therapeutic approaches. </description>
    </item> <item>
      <title>Signaling pathways involved in the development of T-cell acute lymphoblastic leukemia (Article)</title>
      <link>http://repub.eur.nl/res/pub/32276/</link>
      <pubDate>2008-04-01T00:00:00Z</pubDate>
      <description></description>
    </item> <item>
      <title>A discriminating messenger RNA signature for bipolar disorder formed by an aberrant expression of inflammatory genes in monocytes (Article)</title>
      <link>http://repub.eur.nl/res/pub/32323/</link>
      <pubDate>2008-04-01T00:00:00Z</pubDate>
      <description>Context: Mood disturbances are associated with an activated inflammatory response system. Objective: To identify a discriminating and coherent expression pattern of proinflammatory genes in monocytes of patients with bipolar disorder. Design: A quantitative polymerase chain reaction (Q-PCR) case-control gene expression study on purified monocytes of bipolar patients, the offspring of bipolar patients, and healthy control participants after having selected 22 discriminating inflammatory genes using whole genome analyses. Setting: Academic research setting in the Netherlands. Patients: Forty-two bipolar patients with 25 healthy controls, 54 offspring of a bipolar parent (13 had a mood disorder and 3 developed one during follow-up), and 70 healthy children underwent Q-PCR. Main Outcome Measure: Inflammatory gene expression levels in monocytes. Results: We detected in the monocytes of bipolar patients a coherent mutually correlating set (signature) of 19 aberrantly expressed (P&lt;.01) messenger RNAs of inflammatory (PDE4B, IL1B, IL6, TNF, TNFAIP3, PTGS2, and PTX3), trafficking (CCL2, CCL7, CCL20, CXCL2, CCR2, and CDC42), survival (BCL2A1 and EMP1), and mitogen-activated protein kinase pathway (MAPK6, DUSP2, NAB2, and ATF3) genes. Twenty-three of 42 bipolar patients (55%) had a positive signature test result vs 7 of 38 healthy controls (18%) (positive test result: positivity for PDE4B, ie, a messenger RNA 1 SD higher than the mean level found in healthy controls, plus 25% of the other genes with similar positive findings). Positive signature test results were also present in 11 of 13 offspring with a mood disorder (85%), 3 of 3 offspring developing a mood disorder (100%), and 17 of 38 euthymic offspring (45%) vs 13 of 70 healthy children (19%). Lithium carbonate and antipsychotic treatment down-regulated the gene expression of most inflammatory genes. Conclusions: The monocytes of a large proportion of bipolar patients and offspring of bipolar parents showed an inflammatory gene expression signature. This coherent set of genes opens new avenues for biomarker development with possibilities for disease prediction in individuals genetically at risk and for the subclassification of bipolar patients who could possibly benefit from anti-inflammatory treatment. </description>
    </item> <item>
      <title>New insights and unresolved issues regarding insertional mutagenesis in X-linked SCID gene therapy (Article)</title>
      <link>http://repub.eur.nl/res/pub/36968/</link>
      <pubDate>2007-11-01T00:00:00Z</pubDate>
      <description>The oncogenic potential of retrovirus-mediated gene therapy has been re-emphasized because four patients developed T-cell acute lymphoblastic leukemia (T-ALL)-like disease from an otherwise successful gene therapy trial for X-linked severe combined immunodeficiency (X-linked SCID). X-linked SCID, a disease caused by inactivating mutations in the IL2Rγ gene, is part of a heterogeneous group of SCIDs characterized by the lack of T cells in conjunction with the absence of B and/or natural killer (NK) cells. Gene therapy approaches are being developed for this group of diseases. In this review we discuss the various forms of SCID in relation to normal T-cell development. In addition, we consider the possible role of LMO2 and other T-ALL oncogenes in the development of adverse effects as seen in the X-linked SCID gene therapy trial. Furthermore, we debate whether the integration near the LMO2 locus is sufficient to result in T-ALL-like proliferations or whether the gamma-retroviral viral expression of the therapeutic IL2RG gene contributes to leukemogenesis. Finally, we review some newly developed murine models that may have added value for gene therapy safety studies.</description>
    </item> <item>
      <title>Wnt signaling and phosphorylation status of β-catenin: Importance of the correct antibody tools [12] (Article)</title>
      <link>http://repub.eur.nl/res/pub/35185/</link>
      <pubDate>2007-10-01T00:00:00Z</pubDate>
      <description></description>
    </item> <item>
      <title>Gammaretrovirus-mediated correction of SCID-X1 is associated with skewed vector integration site distribution in vivo (Article)</title>
      <link>http://repub.eur.nl/res/pub/35269/</link>
      <pubDate>2007-08-01T00:00:00Z</pubDate>
      <description>We treated 10 children with X-linked SCID (SCID-X1) using gammaretrovirus-mediated gene transfer. Those with sufficient follow-up were found to have recovered substantial immunity in the absence of any serious adverse events up to 5 years after treatment. To determine the influence of vector integration on lymphoid reconstitution, we compared retroviral integration sites (RISs) from peripheral blood CD3+T lymphocytes of 5 patients taken between 9 and 30 months after transplantation with transduced CD34+progenitor cells derived from 1 further patient and 1 healthy donor. Integration occurred preferentially in gene regions on either side of transcription start sites, was clustered, and correlated with the expression level in CD34+progenitors during transduction. In contrast to those in CD34+cells, RISs recovered from engrafted CD3+T cells were significantly overrepresented within or near genes encoding proteins with kinase or transferase activity or involved in phosphorus metabolism. Although gross patterns of gene expression were unchanged in transduced cells, the divergence of RIS target frequency between transduced progenitor cells and post-thymic T lymphocytes indicates that vector integration influences cell survival, engraftment, or proliferation.</description>
    </item> <item>
      <title>Vector integration is nonrandom and clustered and influences the fate of lymphopoiesis in SCID-X1 gene therapy (Article)</title>
      <link>http://repub.eur.nl/res/pub/35291/</link>
      <pubDate>2007-08-01T00:00:00Z</pubDate>
      <description>Recent reports have challenged the notion that retroviruses and retroviral vectors integrate randomly into the host genome. These reports pointed to a strong bias toward integration in and near gene coding regions and, for gammaretroviral vectors, around transcription start sites. Here, we report the results obtained from a large-scale mapping of 572 retroviral integration sites (RISs) isolated from cells of 9 patients with X-linked SCID (SCID-X1) treated with a retrovirus-based gene therapy protocol. Our data showed that two-thirds of insertions occurred in or very near to genes, of which more than half were highly expressed in CD34+progenitor cells. Strikingly, one-fourth of all integrations were clustered as common integration sites (CISs). The highly significant incidence of CISs in circulating T cells and the nature of their locations indicate that insertion in many gene loci has an influence on cell engraftment, survival, and proliferation. Beyond the observed cases of insertional mutagenesis in 3 patients, these data help to elucidate the relationship between vector insertion and long-term in vivo selection of transduced cells in human patients with SCID-X1.</description>
    </item> <item>
      <title>Novel insights into the development of T-cell acute lymphoblastic leukemia (Article)</title>
      <link>http://repub.eur.nl/res/pub/37001/</link>
      <pubDate>2007-07-01T00:00:00Z</pubDate>
      <description>T-cell acute lymphoblastic leukemia (T-ALL) results from malignant transformation of immature cells of the T-cell lineage. T-ALL is a heterogeneous disease both clinically and genetically. It is generally accepted that T-ALL cells are the malignant counterpart of normally developing T cells in the thymus (thymocytes). Recent data using genome-wide gene expression profiling and assessment of the rearrangement status of the T-cell receptor loci confirm this notion. T-ALL cells differ from normal thymocytes in the overexpression of oncogenes that arise either from chromosomal translocations or via other mechanisms. In addition, signaling pathways that control the very first stages of thymocyte development (of note, the Notch and Wnt pathways) are involved in development of T-ALL in mice and humans when constitutively expressed. In particular, the activating mutations in the Notch pathways are believed to occur in a large proportion of human T-ALL. These findings on genetic events open up new therapeutic possibilities. Copyright </description>
    </item> <item>
      <title>Uncontrolled Wnt signaling causes leukemia (Article)</title>
      <link>http://repub.eur.nl/res/pub/35365/</link>
      <pubDate>2007-06-15T00:00:00Z</pubDate>
      <description></description>
    </item> <item>
      <title>Ectopic retroviral expression of LMO2, but not IL2Rγ, blocks human T-cell development from CD34+ cells: Implications for leukemogenesis in gene therapy (Article)</title>
      <link>http://repub.eur.nl/res/pub/36301/</link>
      <pubDate>2007-04-01T00:00:00Z</pubDate>
      <description>The occurrence of leukemia in a gene therapy trial for SCID-X1 has highlighted insertional mutagenesis as an adverse effect. Although retroviral integration near the T-cell acute lymphoblastic leukemia (T-ALL) oncogene LIM-only protein 2 (LMO2) appears to be a common event, it is unclear why LMO2 was preferentially targeted. We show that of classical T-ALL oncogenes, LMO2 is most highly transcribed in CD34+ progenitor cells. Upon stimulation with growth factors typically used in gene therapy protocols transcription of LMO2, LYL1, TAL1 and TAN1 is most prominent. Therefore, these oncogenes may be susceptible to viral integration. The interleukin-2 receptor gamma chain (IL2Rγ), which is mutated in SCID-X1, has been proposed as a cooperating oncogene to LMO2. However, we found that overexpressing IL2Rγ had no effect on T-cell development. In contrast, retroviral overexpression of LMO2 in CD34+ cells caused severe abnormalities in T-cell development, but B-cell and myeloid development remained unaffected. Our data help explain why LMO2 was preferentially targeted over many of the other known T-ALL oncogenes. Furthermore, during T-cell development retrovirus-mediated expression of IL2Rγ may not be directly oncogenic. Instead, restoration of normal IL7-receptor signaling may allow progression of T-cell development to stages where ectopic LMO2 expression causes aberrant thymocyte growth.</description>
    </item> <item>
      <title>Retroviral vector insertion sites associated with dominant hematopoietic clones mark "stemness" pathways (Article)</title>
      <link>http://repub.eur.nl/res/pub/35566/</link>
      <pubDate>2007-03-01T00:00:00Z</pubDate>
      <description>Evidence from model organisms and clinical trials reveals that the random insertion of retrovirus-based vectors in the genome of long-term repopulating hematopoietic cells may increase self-renewal or initiate malignant transformation. Clonal dominance of nonmalignant cells is a particularly interesting phenotype as it may be caused by the dysregulation of genes that affect self-renewal and competitive fitness. We have accumulated 280 retrovirus vector insertion sites (RVISs) from murine long-term studies resulting in benign or malignant clonal dominance. RVISs (22.5%) are located in or near (up to 100 kb [kilobase]) to known proto-oncogenes, 49.6% in signaling genes, and 27.9% in other or unknown genes. The resulting insertional dominance database (IDDb) shows substantial overlaps with the transcriptome of hematopoietic stem/progenitor cells and the retrovirus-tagged cancer gene database (RTCGD). RVISs preferentially marked genes with high expression in hematopoietic stem/progenitor cells, and Gene Ontology revealed an overrepresentation of genes associated with cell-cycle control, apoptosis signaling, and transcriptional regulation, including major "stemness" pathways. The IDDb forms a powerful resource for the identification of genes that stimulate or transform hematopoietic stem/progenitor cells and is an important reference for vector biosafety studies in human gene therapy. </description>
    </item> <item>
      <title>T-, B- and NK-lymphoid, but not myeloid cells arise from human CD34+CD38-CD7+ common lymphoid progenitors expressing lymphoid-specific genes (Article)</title>
      <link>http://repub.eur.nl/res/pub/36332/</link>
      <pubDate>2007-02-01T00:00:00Z</pubDate>
      <description>Hematopoietic stem cells in the bone marrow (BM) give rise to all blood cells. According to the classic model of hematopoiesis, the differentiation paths leading to the myeloid and lymphoid lineages segregate early. A candidate 'common lymphoid progenitor' (CLP) has been isolated from CD34+CD38-human cord blood cells based on CD7 expression. Here, we confirm the B- and NK-differentiation potential of CD34+CD38-CD7+cells and show in addition that this population has strong capacity to differentiate into T cells. As CD34+CD38-CD7+cells are virtually devoid of myeloid differentiation potential, these cells represent true CLPs. To unravel the molecular mechanisms underlying lymphoid commitment, we performed genome-wide gene expression profiling on sorted CD34+CD38-CD7+and CD34+CD38-CD7-cells. Interestingly, lymphoid-affiliated genes were mainly upregulated in the CD7+population, while myeloid-specific genes were downregulated. This supports the hypothesis that lineage commitment is accompanied by the shutdown of inappropriate gene expression and the upregulation of lineage-specific genes. In addition, we identified several highly expressed genes that have not been described in hematopoiesis before.</description>
    </item> <item>
      <title>The effect of oligonucleotide microarray data pre-processing on the analysis of patient-cohort studies. (Article)</title>
      <link>http://repub.eur.nl/res/pub/13984/</link>
      <pubDate>2006-03-02T00:00:00Z</pubDate>
      <description>BACKGROUND: Intensity values measured by Affymetrix microarrays have to be both normalized, to be able to compare different microarrays by removing non-biological variation, and summarized, generating the final probe set expression values. Various pre-processing techniques, such as dChip, GCRMA, RMA and MAS have been developed for this purpose. This study assesses the effect of applying different pre-processing methods on the results of analyses of large Affymetrix datasets. By focusing on practical applications of microarray-based research, this study provides insight into the relevance of pre-processing procedures to biology-oriented researchers. RESULTS: Using two publicly available datasets, i.e., gene-expression data of 285 patients with Acute Myeloid Leukemia (AML, Affymetrix HG-U133A GeneChip) and 42 samples of tumor tissue of the embryonal central nervous system (CNS, Affymetrix HuGeneFL GeneChip), we tested the effect of the four pre-processing strategies mentioned above, on (1) expression level measurements, (2) detection of differential expression, (3) cluster analysis and (4) classification of samples. In most cases, the effect of pre-processing is relatively small compared to other choices made in an analysis for the AML dataset, but has a more profound effect on the outcome of the CNS dataset. Analyses on individual probe sets, such as testing for differential expression, are affected most; supervised, multivariate analyses such as classification are far less sensitive to pre-processing. CONCLUSION: Using two experimental datasets, we show that the choice of pre-processing method is of relatively minor influence on the final analysis outcome of large microarray studies whereas it can have important effects on the results of a smaller study. The data source (platform, tissue homogeneity, RNA quality) is potentially of bigger importance than the choice of pre-processing method.</description>
    </item> <item>
      <title>Wnt signaling in the thymus is regulated by differential expression of intracellular signaling molecules. (Article)</title>
      <link>http://repub.eur.nl/res/pub/13983/</link>
      <pubDate>2006-02-28T00:00:00Z</pubDate>
      <description>Wnt signaling is essential for T cell development in the thymus, but the stages in which it occurs and the molecular mechanisms underlying Wnt responsiveness have remained elusive. Here we examined Wnt signaling activity in both human and murine thymocyte populations by determining beta-catenin levels, Tcf-reporter activation and expression of Wnt-target genes. We demonstrate that Wnt signaling occurs in all thymocyte subsets, including the more mature populations, but most prominently in the double negative (DN) subsets. This differential sensitivity to Wnt signaling was not caused by differences in the presence of Wnts or Wnt receptors, as these appeared to be expressed at comparable levels in all thymocyte subsets. Rather, it can be explained by high expression of activating signaling molecules in DN cells, e.g., beta-catenin, plakoglobin, and long forms of Tcf-1, and by low levels of inhibitory molecules. By blocking Wnt signaling from the earliest stage onwards using overexpression of Dickkopf, we show that inhibition of the canonical Wnt pathway blocks development at the most immature DN1 stage. Thus, responsiveness to developmental signals can be regulated by differential expression of intracellular mediators rather than by abundance of receptors or ligands.</description>
    </item> <item>
      <title>New insights on human T cell development by quantitative T cell receptor gene rearrangement studies and gene expression profiling (Article)</title>
      <link>http://repub.eur.nl/res/pub/8406/</link>
      <pubDate>2005-01-01T00:00:00Z</pubDate>
      <description>To gain more insight into initiation and regulation of T cell receptor
      (TCR) gene rearrangement during human T cell development, we analyzed TCR
      gene rearrangements by quantitative PCR analysis in nine consecutive T
      cell developmental stages, including CD34+ lin- cord blood cells as a
      reference. The same stages were used for gene expression profiling using
      DNA microarrays. We show that TCR loci rearrange in a highly ordered way
      (TCRD-TCRG-TCRB-TCRA) and that the initiating Ddelta2-Ddelta3
      rearrangement occurs at the most immature CD34+CD38-CD1a- stage. TCRB
      rearrangement starts at the CD34+CD38+CD1a- stage and complete in-frame
      TCRB rearrangements were first detected in the immature single positive
      stage. TCRB rearrangement data together with the PTCRA (pTalpha)
      expression pattern show that human TCRbeta-selection occurs at the
      CD34+CD38+CD1a+ stage. By combining the TCR rearrangement data with gene
      expression data, we identified candidate factors for the
      initiation/regulation of TCR recombination. Our data demonstrate that a
      number of key events occur earlier than assumed previously; therefore,
      human T cell development is much more similar to murine T cell development
      than reported before.</description>
    </item> <item>
      <title>Wnt target genes identified by DNA microarrays in immature CD34+ thymocytes regulate proliferation and cell adhesion (Article)</title>
      <link>http://repub.eur.nl/res/pub/10281/</link>
      <pubDate>2004-01-01T00:00:00Z</pubDate>
      <description>The thymus is seeded by very small numbers of progenitor cells that
      undergo massive proliferation before differentiation and rearrangement of
      TCR genes occurs. Various signals mediate proliferation and
      differentiation of these cells, including Wnt signals. Wnt signals induce
      the interaction of the cytoplasmic cofactor beta-catenin with nuclear T
      cell factor (TCF) transcription factors. We identified target genes of the
      Wnt/beta-catenin/TCF pathway in the most immature (CD4-CD8-CD34+)
      thymocytes using Affymetrix DNA microarrays in combination with three
      different functional assays for in vitro induction of Wnt signaling. A
      relatively small number (approximately 30) of genes changed expression,
      including several proliferation-inducing transcription factors such as
      c-fos and c-jun, protein phosphatases, and adhesion molecules, but no
      genes involved in differentiation to mature T cell stages. The adhesion
      molecules likely confine the proliferating immature thymocytes to the
      appropriate anatomical sites in the thymus. For several of these target
      genes, we validated that they are true Wnt/beta-catenin/TCF target genes
      using real-time quantitative PCR and reporter gene assays. The same core
      set of genes was repressed in Tcf-1-null mice, explaining the block in
      early thymocyte development in these mice. In conclusion, Wnt signals
      mediate proliferation and cell adhesion, but not differentiation of the
      immature thymic progenitor pool.</description>
    </item> <item>
      <title>Wnt signals are transmitted through N-terminally dephosphorylated beta-catenin. (Article)</title>
      <link>http://repub.eur.nl/res/pub/13000/</link>
      <pubDate>2002-02-26T00:00:00Z</pubDate>
      <description>beta-catenin mediates Wnt signaling by acting as the essential co-activator for TCF transcription factors. Wnt signaling increases the half-life and therefore the absolute level of beta-catenin in responding cells. The current model states that these changes in beta-catenin stability set the threshold for Wnt signaling. However, we find that pharmacological inhibition of proteasome activity by ALLN leads to accumulation of cytosolic beta-catenin but not to increased TCF-mediated transcription. In addition, in temperature-sensitive ubiquitylation mutant CHO cells inhibition of ubiquitylation increases beta-catenin levels, but does not induce transcriptional activation of TCF reporter genes. Using an antibody specific for beta-catenin dephosphorylated at residues Ser37 and Thr41, we show that Wnt signals specifically increase the levels of dephosphorylated beta-catenin, whereas ALLN does not. We conclude that changes in the phosphorylation status of the N-terminus of beta-catenin that occur upon Wnt signaling independently affect the signaling properties and half-life of beta-catenin. Hence, Wnt signals are transduced via N-terminally dephosphorylated beta-catenin.</description>
    </item> <item>
      <title>Transcriptional control of t lymphocyte differentiation (Article)</title>
      <link>http://repub.eur.nl/res/pub/9637/</link>
      <pubDate>2001-01-01T00:00:00Z</pubDate>
      <description>Initiation of gene transcription by transcription factors (TFs) is an
          important regulatory step in many developmental processes. The
          differentiation of T cell progenitors in the thymus is tightly controlled
          by signaling molecules, ultimately activating nuclear TFs that regulate
          the expression of T lineage-specific genes. During the last 2 years,
          significant progress has been made in our understanding of the signaling
          routes and TFs operating during the earliest stages of thymic
          differentiation at the CD4(-)CD8(-) double negative stage. Here we will
          review the TF families that play an important role in differentiation of
          thymocytes, particularly focusing on recent new information with respect
          to the Tcf, bHLH, GATA, and CBF/HES TF families.</description>
    </item>
  </channel>
</rss>